Bupivacaine-induced myotoxicity and its effect on botulinum toxin paresis

Annals of Plastic Surgery

Volumn 60, Issue 1, 2008, Pages 6-9

  Yen, Michael T ^a   Wall, Victoria K ^a  

^a CULLEN EYE INSTITUTE   (United States)

Author keywords

Botox; Botulinum toxin; Bupivacaine; Glabella; Marcaine

Indexed keywords

BOTULINUM TOXIN A; BUPIVACAINE; NEUROTOXIN; NEUTRALIZING ANTIBODY;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; MALE; MIGRAINE; MUSCLE CONTRACTION; MUSCLE NECROSIS; MUSCLE WEAKNESS; PARALYSIS; PARESIS; PLASTIC SURGERY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TENSION HEADACHE;

ANESTHETICS, LOCAL; BOTULINUM TOXIN TYPE A; BUPIVACAINE; DRUG SYNERGISM; FEMALE; HUMANS; MALE; NEUROMUSCULAR AGENTS; PARESIS; PROSPECTIVE STUDIES;

EID: 39849095756     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/SAP.0b013e318045a083     Document Type: Article

References (16)

1. Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol. 2001;248(suppl 1):3-10.
2. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044-1049.
3. de Paiva A, Meunier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96:3200-3205.
4. Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord. 1998;13:150-154.
5. Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005;20:592-597.
6. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency: German Dystonia Study Group. J Neurol. 1999;246:265-274.
7. Foster AH, Carlson BM. Myotoxicity of local anesthetics and regeneration of the damaged muscle fibers. Anesth Analg. 1980;59:727-776.
8. Hogan Q, Dotson R, Erickson S, et al. Local anesthetic myotoxicity: a case and review. Anesthesiology. 1994;80:942-947.
9. Porter JD, Edney DP, McMahon EJ, et al. Extraocular myotoxicity of the retrobulbar anesthetic bupivacaine hydrochloride. Invest Ophthalmol Vis Sci. 1988;29:163-174.
10. Gǒrgǔ M, Silistreli Ǒ K, Karantinaci B, et al. Interaction of botulinum toxin type a with local anesthetic agents: an experimental study with rabbits. Aesthetic Plast Surg. 2006;30:59-64.
11. Nguyen LT, McLoon LK, Wirtschafter JD. Doxorubicin chemomyectomy is enhanced when performed two days following bupivacaine injections: the effect coincides with the peak of muscle satellite cell division. Invest Ophthalmol Vis Sci. 1998;39:203-206.
12. Setler PE. Therapeutic uses of botulinum toxins: background and history. Clin J Pain. 2002;18(6 suppl):S119-124.
13. Gassner HG, Sherris DA. Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin type A injections: a randomized controlled study. Mayo Clin Proc. 2000;75:701-704.
14. Linder IS, Edmonson BC, Laquis SJ, et al. Skin cooling before periocular botulinum toxin A injection. Ophthal Plast Reconstr Surg. 2002;18:441-442.
15. Soylev MF, Kocak N, Kuvaki B, et al. Anesthesia with EMLA cream for botulinum A toxin injection into eyelids. Ophthalmologica. 2002;216:355-358.
16. Sami MS, Soparkar CNS, Patrinely JR, et al. Efficacy of botulinum toxin type A after topical anesthesia. Ophthal Plast Reconstr Surg. 2006;22:448-452.